Rallybio Corp (RLYB) stock
Close on Nov 12, 2026Market cap $84.26MP/E 3.4Yield –
Rallybio Corp saw revenue fall 35.6% to $434.00K over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $84.26M, 3.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $84.26M
- P/E ratio
- 3.4
- Price to sales
- 194.14
- Price to book
- 0.91
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $434.00K
- Net income
- $26.81M
- EPS, diluted
- $4.56
- Book value per share
- $16.15
- Diluted shares
- 6M
Trading
- Previous close
- $15.80
- Open
- $15.89
- Day's range
- $15.51 – $15.95
- Volume
- 23,336
- Average volume (20 days)
- 37,320
- Beta (5 years)
- 0.63
- 52-week range
- $3.67 – $17.57
- RSI (14 days)
- 39.2
- Volatility (1 year)
- 84.3%
- Relative volume
- 0.96×
- WACC
- 8.1%
On 2 of our idea lists: Net-nets, More cash than they're worth
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | RLYB | S&P 500 | Difference | RLYB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.8% | -2.7% | −4.1 pts | ||
| 3 months | -5.7% | -1.7% | −3.9 pts | ||
| Year to date | +185.1% | +11.9% | +173.2 pts | ||
| 1 year | +180.2% | +12.0% | +168.2 pts | ||
| 3 years | -31.8% | +78.2% | −110.0 pts | -12.0% | +21.2% |
| 5 years | -87.0% | +73.2% | −160.2 pts | -33.5% | +11.6% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Rallybio filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- Update
About Rallybio
Pharmaceutical Preparations
Rallybio Corporation is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapeutic candidates for individuals affected by severe and rare diseases. The company's pipeline centers on candidate treatments for complement dysregulation and hematological disorders. Its lead investigational asset is RLYB116, a complement component 5 inhibitor designed for subcutaneous administration to treat rare complement-mediated conditions. Rallybio is also developing RLYB332, a preclinical matriptase-2 antibody targeting diseases characterized by ineffective erythropoiesis and iron overload. The business further engages in research collaborations with industry partners to discover antibody-based therapies for rare metabolic and other disorders.
Company profile, executives and historyRallybio stock: common questions
What is Rallybio's stock price?
RLYB closed at $15.65 on Nov 12, 2026, down 0.95% on the day. Over the past 52 weeks it traded between $3.67 and $17.57.
What is Rallybio's market cap?
Rallybio was worth $84.26M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is RLYB's P/E ratio?
RLYB trades at 3.4 times earnings, based on diluted earnings per share of $4.56 over the twelve months to Sep 30, 2026.
How much revenue does Rallybio make?
Rallybio reported revenue of $434.00K for the twelve months to Sep 30, 2026, down 35.6% from a year earlier.
Does Rallybio pay a dividend?
No. Rallybio has not paid a cash dividend over the last twelve months.
How has RLYB stock performed over the past year?
Including dividends, RLYB returned +180.2% over the past year, against +12.0% for the S&P 500.
How many RLYB shares are sold short?
0M shares were sold short at the latest FINRA report, 2.65% of the float, or 1.2 days of average trading volume.
Who are Rallybio's competitors?
Companies most similar to Rallybio by business, industry and size include MREO, YARW, VCNX, SLN, CANF.
See a number that looks wrong?